Free Trial
NASDAQ:VNDA

Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

Vanda Pharmaceuticals logo
$4.78 +0.02 (+0.32%)
As of 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)

Key Stats

Today's Range
$4.74
$4.88
50-Day Range
$3.92
$5.02
52-Week Range
$3.81
$6.36
Volume
387,968 shs
Average Volume
577,977 shs
Market Capitalization
$281.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50
Consensus Rating
Strong Buy

Company Overview

Vanda Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

VNDA MarketRank™: 

Vanda Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 68th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vanda Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Vanda Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Vanda Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($1.12) to ($0.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vanda Pharmaceuticals is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vanda Pharmaceuticals is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vanda Pharmaceuticals has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Vanda Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.68% of the float of Vanda Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vanda Pharmaceuticals has recently decreased by 96.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vanda Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Vanda Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.68% of the float of Vanda Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vanda Pharmaceuticals has recently decreased by 96.41%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Vanda Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Vanda Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vanda Pharmaceuticals insiders have bought 299.63% more of their company's stock than they have sold. Specifically, they have bought $128,400.00 in company stock and sold $32,130.00 in company stock.

  • Percentage Held by Insiders

    Only 8.90% of the stock of Vanda Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vanda Pharmaceuticals' insider trading history.
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Stock News Headlines

I warned you about Nvidia… now look what’s happening
Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.
VNDA - Vanda Pharmaceuticals Inc Chart - Morningstar
See More Headlines

VNDA Stock Analysis - Frequently Asked Questions

Vanda Pharmaceuticals' stock was trading at $4.79 at the beginning of 2025. Since then, VNDA stock has increased by 0.7% and is now trading at $4.8250.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its earnings results on Wednesday, May, 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.05. The biopharmaceutical company earned $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 8.30% and a negative net margin of 21.98%.
Read the conference call transcript
.

Vanda Pharmaceuticals' top institutional shareholders include Public Employees Retirement System of Ohio (0.06%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Kevin Patrick Moran, Joakim Wijkstrom, Stephen Ray Mitchell and Timothy Williams.
View institutional ownership trends
.

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/07/2025
Today
7/16/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VNDA
CIK
1347178
Employees
290
Year Founded
2002

Price Target and Rating

High Price Target
$20.00
Low Price Target
$13.00
Potential Upside/Downside
+246.6%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.90 million
Net Margins
-21.98%
Pretax Margin
-27.63%
Return on Equity
-8.30%
Return on Assets
-6.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.93
Quick Ratio
3.91

Sales & Book Value

Annual Sales
$198.77 million
Price / Sales
1.41
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.24 per share
Price / Book
0.52

Miscellaneous

Outstanding Shares
58,930,000
Free Float
53,689,000
Market Cap
$280.51 million
Optionable
Optionable
Beta
0.68

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:VNDA) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners